Trade War‘s Next Frontier? China Genetic Material Regs Could Set Back Biopharma Research

A new rule regulating the collecting, storing and transporting of genetic samples and materials in China sets new limits on international companies looking to conduct work with biologic and gene therapies in potentially the most promising market for these emerging technologies.

3D Human or animal Cell
CHINA SIMPLIFIES GENETIC REGULATION BUT CAUSES IP CONCERNS • Source: Shutterstock

A new regulation in China governing the collection, storage and transport of human genetic samples, including blood, saliva, tissues and cells, is expected to have a profound impact on biopharmaceutical R&D in the country, one of the most promising markets globally for this area of therapy.

The regulation has been seven years in the making after work was initiated back in 2012, and is set to...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from China

More from Asia